| Product Code: ETC7628470 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Ireland Dopamine Agonist Drug Market Overview |
3.1 Ireland Country Macro Economic Indicators |
3.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, 2021 & 2031F |
3.3 Ireland Dopamine Agonist Drug Market - Industry Life Cycle |
3.4 Ireland Dopamine Agonist Drug Market - Porter's Five Forces |
3.5 Ireland Dopamine Agonist Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Ireland Dopamine Agonist Drug Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Ireland Dopamine Agonist Drug Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.8 Ireland Dopamine Agonist Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Ireland Dopamine Agonist Drug Market Revenues & Volume Share, By End- Users, 2021 & 2031F |
3.10 Ireland Dopamine Agonist Drug Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Ireland Dopamine Agonist Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurological disorders in Ireland |
4.2.2 Growing awareness and diagnosis of Parkinson's disease and related conditions |
4.2.3 Advancements in medical research leading to new dopamine agonist drug developments |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval process for new drugs in Ireland |
4.3.2 High cost associated with dopamine agonist drugs |
4.3.3 Potential side effects and risks associated with prolonged use of dopamine agonists |
5 Ireland Dopamine Agonist Drug Market Trends |
6 Ireland Dopamine Agonist Drug Market, By Types |
6.1 Ireland Dopamine Agonist Drug Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Non-Ergoline Dopamine Agonists, 2021- 2031F |
6.1.4 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Ergot-Derived Dopamine Agonists, 2021- 2031F |
6.1.5 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Recombinant Factor VIII, 2021- 2031F |
6.1.6 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Ireland Dopamine Agonist Drug Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Parkinson's Disease, 2021- 2031F |
6.2.3 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Restless Leg Syndrome, 2021- 2031F |
6.2.4 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Ireland Dopamine Agonist Drug Market, By Drugs |
6.3.1 Overview and Analysis |
6.3.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Carbidopa and Levodopa, 2021- 2031F |
6.3.3 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Ropinirole, 2021- 2031F |
6.3.4 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Pramipexole, 2021- 2031F |
6.3.5 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Cabergoline, 2021- 2031F |
6.3.6 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Bromocriptine, 2021- 2031F |
6.3.7 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Ireland Dopamine Agonist Drug Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Injectable, 2021- 2031F |
6.5 Ireland Dopamine Agonist Drug Market, By End- Users |
6.5.1 Overview and Analysis |
6.5.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Ireland Dopamine Agonist Drug Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.6.3 Ireland Dopamine Agonist Drug Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
7 Ireland Dopamine Agonist Drug Market Import-Export Trade Statistics |
7.1 Ireland Dopamine Agonist Drug Market Export to Major Countries |
7.2 Ireland Dopamine Agonist Drug Market Imports from Major Countries |
8 Ireland Dopamine Agonist Drug Market Key Performance Indicators |
8.1 Number of neurologists specializing in movement disorders in Ireland |
8.2 Research and development expenditure in the pharmaceutical industry focusing on dopamine agonist drugs |
8.3 Patient adherence and compliance rates with dopamine agonist drug therapy |
9 Ireland Dopamine Agonist Drug Market - Opportunity Assessment |
9.1 Ireland Dopamine Agonist Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Ireland Dopamine Agonist Drug Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Ireland Dopamine Agonist Drug Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.4 Ireland Dopamine Agonist Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Ireland Dopamine Agonist Drug Market Opportunity Assessment, By End- Users, 2021 & 2031F |
9.6 Ireland Dopamine Agonist Drug Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Ireland Dopamine Agonist Drug Market - Competitive Landscape |
10.1 Ireland Dopamine Agonist Drug Market Revenue Share, By Companies, 2024 |
10.2 Ireland Dopamine Agonist Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here